Swedbank Ab Novo Cure LTD Transaction History

Swedbank Ab

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Dec 09, 2024	SELL	$16.15 - $42.35 $1.41 Million - $3.7 Million	-87,340 Closed	0 $0
Q2 2023 Dec 09, 2024	SELL	$40.29 - $82.51 $48,348 - $99,012	-1,200 Reduced 1.36%	87,340 $3.62 Million
Q1 2023 Dec 09, 2024	SELL	$56.44 - $118.81 $22,576 - $47,524	-400 Reduced 0.45%	88,540 $5.32 Million
Q4 2022 Dec 09, 2024	BUY	$63.98 - $85.37 $6,398 - $8,537	100 Added 0.11%	88,940 $6.52 Million
Q2 2022 Dec 09, 2024	BUY	$56.6 - $89.9 $650,900 - $1.03 Million	11,500 Added 14.87%	88,840 $6.17 Million
Q1 2022 Dec 09, 2024	BUY	$60.15 - $84.52 $2.94 Million - $4.13 Million	48,900 Added 171.94%	77,340 $6.41 Million
Q4 2021 Dec 09, 2024	BUY	$75.08 - $121.99 $15,016 - $24,398	200 Added 0.71%	28,440 $2.14 Million
Q3 2021 Dec 09, 2024	BUY	$116.17 - $194.55 $587,123 - $983,255	5,054 Added 21.8%	28,240 $3.28 Million
Q2 2021 Dec 09, 2024	BUY	$130.4 - $225.58 $3.02 Million - $5.23 Million	23,186 New	23,186 $5.14 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.25B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Swedbank Ab, based on Form 13F filings with the SEC.

Stay updated on Swedbank Ab with notifications on news.